Celator Pharmaceuticals, Inc.,founded in 2000, is a privately held biopharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex, the company’s drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on the optimal ratio of drug agents to target cancer cells effectively. The company pipeline includes: CPX-1 as a treatment option for colorectal cancer; CPX-351 as a treatment for leukemia, CPX 571 which targets small cell lung cancer.